Farxiga (Dapagliflozin) Cost in Missouri: Prices, Insurance, and Savings in 2026

What Farxiga Actually Costs at Missouri Pharmacies in 2026

The average cash price for a 30-day supply of Farxiga 10 mg at Missouri retail pharmacies sits at approximately $620 in 2026, matching AstraZeneca's national list price. That figure reflects the amount an uninsured patient would pay at chains like Walgreens, CVS, or Walmart locations across the state. Prices can vary by $20 to $50 between pharmacies in the same metro area.

Independent pharmacies in St. Louis, Kansas City, and Springfield sometimes price Farxiga slightly below the chain average, though the difference rarely exceeds 5% to 8%. GoodRx and RxSaver coupons may bring the out-of-pocket cost down to roughly $530 to $570 at select locations, but coupon pricing fluctuates weekly. These discount tools do not apply when billing insurance.

Dapagliflozin belongs to the SGLT2 inhibitor class. The FDA-approved prescribing information lists three indications: improving glycemic control in type 2 diabetes, reducing hospitalization for heart failure with reduced ejection fraction, and slowing eGFR decline in chronic kidney disease [1]. Each indication carries its own prior authorization pathway at Missouri insurers, which directly affects what patients pay.

Missouri Medicaid Coverage: What Gets Approved and What Does Not

Missouri Medicaid (MO HealthNet) does not cover Farxiga when prescribed solely for type 2 diabetes. Preferred formulary agents for T2D under MO HealthNet include metformin, sulfonylureas, and select DPP-4 inhibitors. SGLT2 inhibitors are classified as non-preferred, and requests for T2D alone are routinely denied at the prior authorization stage.

The picture changes for heart failure and CKD. The DAPA-HF trial (N=4,744) demonstrated that dapagliflozin 10 mg reduced the composite of worsening heart failure or cardiovascular death by 26% compared with placebo (HR 0.74; 95% CI, 0.65 to 0.85; P<0.001) in patients with HFrEF [2]. Based on that evidence, the American College of Cardiology/American Heart Association 2022 heart failure guidelines gave SGLT2 inhibitors a Class I recommendation for HFrEF regardless of diabetes status [3]. Missouri Medicaid may authorize Farxiga under a medical exception when the prescriber documents a heart failure or CKD diagnosis and prior trial of formulary alternatives.

Dr. Mikhail Kosiborod, a cardiologist at Saint Luke's Mid America Heart Institute in Kansas City, has stated: "SGLT2 inhibitors have moved from diabetes drugs to cardiovascular medicines. The benefits in heart failure are independent of glycemic status" [4]. That clinical framing can support prior authorization appeals for Missouri patients whose initial requests are denied.

To file a MO HealthNet prior authorization, prescribers submit form MO-838 through the Gainwell Technologies portal or fax it to (573) 635-3849. Turnaround is typically 24 to 72 hours. Appeals require a letter of medical necessity citing guideline-concordant evidence.

How Missouri Commercial Insurance Plans Handle Farxiga

Most major commercial plans operating in Missouri, including UnitedHealthcare, Anthem Blue Cross Blue Shield, Cigna, and Aetna, place Farxiga on formulary tier 3 (preferred brand) or tier 4 (non-preferred brand). Tier placement determines the copay structure.

Tier 3 copays in Missouri typically range from $40 to $75 per fill. Tier 4 copays may run $75 to $150. Plans with coinsurance instead of flat copays charge 25% to 50% of the negotiated price, which can mean $100 to $200 out of pocket before meeting the deductible. Patients on high-deductible health plans face the full $620 until the deductible is satisfied.

Prior authorization is standard. Most Missouri commercial plans require documentation of metformin trial (or contraindication) before approving dapagliflozin for T2D. For heart failure and CKD indications, plans may waive the metformin step given the 2022 AHA/ACC guideline recommendations [3]. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced the risk of sustained eGFR decline, end-stage kidney disease, or renal/cardiovascular death by 39% versus placebo (HR 0.61; 95% CI, 0.51 to 0.72; P<0.001) [5]. Citing DAPA-CKD strengthens CKD-related prior authorization requests.

Missouri marketplace (ACA) plans sold through healthcare.gov follow similar formulary rules. Silver and Gold tier plans generally offer lower copays for brand medications. Bronze plans pair lower premiums with higher drug cost-sharing, making manufacturer assistance programs more relevant for those enrollees.

The AstraZeneca Savings Card: Eligibility and Missouri-Specific Details

AstraZeneca offers an official Farxiga savings card that reduces copays for commercially insured patients. Eligible patients may pay as little as $0 per 30-day fill, with AstraZeneca covering up to $300 per prescription. The card is reusable for up to 24 months.

Eligibility requirements are straightforward. The patient must carry commercial insurance (employer-sponsored, marketplace, or individual). Government insurance disqualifies: Medicare, Medicaid, Tricare, and VA beneficiaries cannot use the card. Missouri residents with commercial coverage can activate the card online or through their prescriber's office.

The card works at any Missouri pharmacy that accepts commercial copay cards. Patients present it alongside their insurance card at the point of sale. The pharmacist processes insurance first, then applies the savings card to whatever copay or coinsurance remains. If the remaining copay is $300 or less, the patient pays nothing.

One limitation applies. Patients whose plans use an accumulator adjustment program may find that savings card dollars do not count toward their annual deductible or out-of-pocket maximum. Missouri has not passed accumulator adjustment legislation as of mid-2026, so plan terms govern. Patients should verify their plan's copay accumulator policy before relying on the savings card to accelerate deductible spend.

Compounded Dapagliflozin in Missouri: Legality, Access, and Cost

Compounded dapagliflozin is legal in Missouri through licensed 503A compounding pharmacies. Under federal law (Drug Quality and Security Act, 2013) and Missouri Board of Pharmacy regulations, a 503A pharmacy may compound dapagliflozin from bulk active pharmaceutical ingredient when it holds a valid prescription for an individual patient [6].

The cost difference is significant. Some Missouri 503A pharmacies advertise compounded dapagliflozin for substantially less than the $620 brand-name price. Exact pricing varies by pharmacy and dose.

Several considerations apply. Compounded medications are not FDA-approved products. They do not undergo the same manufacturing, testing, and labeling standards as commercially manufactured Farxiga. The FDA guidance on compounding states that compounded drugs "are not FDA-approved" and "may or may not meet federal quality standards" [7]. Patients and prescribers should weigh the cost savings against the lack of FDA manufacturing oversight.

Missouri-licensed 503A pharmacies must compound in response to individual prescriptions. They cannot compound in anticipation of demand (that activity falls under 503B outsourcing facility rules). Prescribers writing for compounded dapagliflozin should confirm the pharmacy holds current Missouri Board of Pharmacy licensure and sources its API from an FDA-registered supplier.

Insurance does not cover compounded dapagliflozin. Patients pay out of pocket. For some patients, particularly those without insurance or those on plans with prohibitively high brand-name copays, compounding offers a viable path to access.

Telehealth Prescribing of Farxiga in Missouri

Missouri permits telehealth prescribing of Farxiga. State law allows prescribers to establish a patient-physician relationship via synchronous audio-video encounter, and dapagliflozin is not a controlled substance, so no in-person visit is required before the first prescription [8].

Several national telehealth platforms serve Missouri patients seeking SGLT2 inhibitor prescriptions. The telehealth prescriber can order baseline labs (HbA1c, eGFR, serum potassium), review results electronically, and transmit the prescription to any Missouri pharmacy. Follow-up visits can remain virtual.

The Endocrine Society clinical practice guideline recommends SGLT2 inhibitors as add-on therapy in T2D patients with established atherosclerotic cardiovascular disease, heart failure, or CKD, regardless of HbA1c level [9]. Telehealth prescribers in Missouri follow these same evidence-based protocols. Patients should confirm that their telehealth provider can handle prior authorization paperwork, as some platforms leave that task to the patient.

Telehealth visits for Farxiga prescriptions typically cost $50 to $150 without insurance. Many commercial plans cover telehealth visits at the standard copay. Missouri Medicaid covers telehealth visits under its existing telemedicine benefit.

How to Reduce Your Farxiga Cost in Missouri: A Step-by-Step Approach

The practical path to the lowest out-of-pocket cost depends on your insurance status.

Commercially insured patients: Request the AstraZeneca savings card first. If your copay after insurance is $300 or less, the card brings it to $0. Ask your plan whether it uses copay accumulators. If it does, the card still reduces your monthly cost, but the savings may not count toward your deductible.

Missouri Medicaid enrollees: If your diagnosis is heart failure or CKD, ask your prescriber to submit a prior authorization citing DAPA-HF or DAPA-CKD trial data and the AHA/ACC guideline recommendation. If your only diagnosis is T2D, MO HealthNet is unlikely to approve coverage. Consider patient assistance or compounding.

Uninsured patients: AstraZeneca's patient assistance program (AZ&Me) provides free Farxiga to qualifying uninsured patients with household income at or below 400% of the federal poverty level [10]. Apply through the AZ&Me portal or by calling 1-800-292-6363. Processing takes 4 to 6 weeks. In the interim, compounded dapagliflozin from a Missouri 503A pharmacy offers an immediate lower-cost option.

Dr. Robert Eckel, past president of the American Heart Association, has noted: "Cost should never be the reason a patient with heart failure or CKD cannot access an SGLT2 inhibitor. Clinicians need to be familiar with every assistance pathway" [11]. That guidance applies directly in Missouri, where the gap between the $620 list price and available discounts is substantial.

Farxiga vs. Other SGLT2 Inhibitors: Missouri Price Comparison

Farxiga is not the only SGLT2 inhibitor available in Missouri. Jardiance (empagliflozin, Boehringer Ingelheim/Lilly) carries a similar list price of approximately $610 to $630 per month. Invokana (canagliflozin, Janssen) lists at roughly $580 to $610. No generic SGLT2 inhibitor is available in the U.S. as of mid-2026.

Formulary positioning differs by plan. Some Missouri commercial plans prefer Jardiance over Farxiga (or vice versa), placing the preferred option on tier 3 and the non-preferred on tier 4. Switching between SGLT2 inhibitors based on formulary status is clinically reasonable for most patients, as the 2022 ADA Standards of Care treat the class as largely interchangeable for T2D [12].

For heart failure specifically, both dapagliflozin and empagliflozin carry FDA approval and Class I guideline recommendations. The EMPEROR-Reduced trial for empagliflozin and DAPA-HF for dapagliflozin showed comparable relative risk reductions [2, 13]. Choosing the formulary-preferred agent can save Missouri patients $30 to $100 per month in copay differences without sacrificing clinical efficacy.